DDInter535 DDInter706
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Corticotropin
Corticotropin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Hydroflumethiazide
Hydroflumethiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is bound by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Diazoxide {u} (Compound) upregulates {v} (Gene) RBM6
RBM6 {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is bound by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Diazoxide (Compound) upregulates RBM6 (Gene) and RBM6 (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide